Compare Moderna, Inc. (MRNA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Koninklijke Philips NV — how do they compare? Moderna, Inc. trades at $135.86 (market cap $56.02B), while Koninklijke Philips NV trades at $25.03 (market cap $24.84B). The key difference: Moderna, Inc. is far larger — about 2.3× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays a 4.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PHG | |
|---|---|---|
Market Cap | $56.02B | $24.84B |
Sector | Health | Health |
52-Week High | $174.38 | $32.91 |
52-Week Low | $22.36 | $25.02 |
Enterprise Value | $52.17B | $31.44B |
Dividend Yield | — | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
PHG trades at $25.29, down 2.32% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.57 versus $0.40 expected, continuing a trend of profitability after a turnaround from losses in prior years. Recent news highlights product launches in health technology and a $33.7 million award for AI-enabled stroke care (Business Wire, 2026-08-26).
The outlook is mixed: fundamentals show improving margins and cash flow, but technical indicators and a majority hold analyst rating suggest near-term caution. Key risks include competitive pressures and execution of growth initiatives, while institutional buying activity indicates underlying confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
